---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-26-001140"
form_type: "8-K"
ticker: "MBRX"
cik: "0001659617"
company_name: "Moleculin Biotech, Inc."
filed_at: "2026-01-13T23:59:59+00:00"
generated_at: "2026-05-16T10:40:45.394968+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Moleculin reports no cardiotoxicity in 90 Annamycin subjects across five trials

## Summary
- Independent expert review of 90 subjects across five clinical trials found no evidence of cardiotoxicity.
- 65 of 90 subjects received cumulative doses above FDA lifetime max of 550 mg/m2; one exceeded 6,500 mg/m2.
- Data reviewed included serial ECGs, echocardiography with global longitudinal strain, and cardiac troponins.
- Trials covered acute myeloid leukemia and soft tissue sarcoma, both as monotherapy and with cytarabine.
- CEO cites potential for Annamycin to become first non-cardiotoxic anthracycline addressing high unmet need.

## SEC filing metadata
- accession: 0001437749-26-001140
- form_type: 8-K
- ticker: MBRX
- cik: 0001659617
- company_name: Moleculin Biotech, Inc.
- filed_at: 2026-01-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659617/000143774926001140/0001437749-26-001140-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659617/000143774926001140/mbrx20260110c_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-26-001140
- JSON: https://secwatch.observer/filing/0001437749-26-001140.json
- Plain text: https://secwatch.observer/filing/0001437749-26-001140.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.